Friday 6 November 2026 Export RLAY’s income statement to Excel — free account

Relay Therapeutics, Inc.

Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.

Revenue: −95.4%
EPS: 0.00%
Free cash flow: +2.13%

Quarter to June 2026, against a year earlier

18.44 1.44 +8.47%

Follow RLAY

Alert me

Market cap: $3.7B
P/E: 0.0×
Fwd P/E: −11.4×
Dividend yield: —
F-score: 5/9
Altman Z: 10.99
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Sold, $m 129.18

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	4	—	1	4	1	3	6	4	3	5	—

Insider Ownership 15.38%

Capital & Financial Ratios $m

Size

Market Cap 3,730.00

Revenue ttm 11.03

Net income ttm (286.04)

Free cash flow ttm (212.20)

Net debt Q (910.93)

Valuation

P/E 0.00

Forward P/E (11.40)

Price / sales 313.49

Forward P/S Powerpack

Price / FCF 0.00

Price / book 3.88

Financial health

Current ratio Q 18.27

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q −95.44%

Operating income growth Q −18.19%

EPS, this year +2.44%

EPS, next year A −1.89%

Revenue, next year A −27.12%

EPS, past 5 yrs —

EPS, next 5 yrs A +0.51%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 58.78%

10-year low 10-year high

P/B against its own 10 years 76.13%

10-year low 10-year high

EV/Sales against its own 10 years 51.50%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	750	781	555	911
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	3	11	6	8
	770	809	578	928

	2023	2024	2025	Q'26
Payables	9	14	8	11
ST’ Debt	—	—	—	—
Other	1	2	0	1
	30	51	26	51

Compound Annual Growth %

	10y	5y	3y
Sales	—	(28.58%)	123.20%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(5.77%)	(15.81%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.40 Actual −0.37

−0.42 −0.39 −0.36 −0.34 −0.31

Q4 FY25 Beat +0.06

Q1 FY26 Miss −0.06

Q2 FY26 Met 0.00

Q3 FY26 Beat +0.03

Q4 FY26 — Feb 25

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY25	−0.38	−0.32	Beat by 0.06
Q1 FY26	−0.35	−0.41	Miss by 0.06
Q2 FY26	−0.41	−0.41	Met by 0.00
Q3 FY26	−0.40	−0.37	Beat by 0.03
Q4 FY26	−0.37	—	Reports 25 February 2027

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.41)	(0.41)	—	—	—
’25	(0.46)	(0.41)	(0.43)	(0.32)	(1.61)
’24	(0.62)	(0.69)	(0.63)	(0.45)	(2.36)
’23	(0.78)	(0.81)	(0.54)	(0.67)	(2.79)
’22	(0.57)	(0.71)	(0.76)	(0.56)	(2.59)
’21	(0.47)	(2.10)	(0.66)	(0.62)	(3.82)
’20	(5.99)	(6.06)	(0.51)	11.33	(5.40)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	0	—	—	—
’25	8	1	—	7	15
’24	10	—	—	—	10
’23	0	0	25	0	26
’22	0	0	0	0	1
’21	1	1	1	1	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(51)	(54)	—	—	—
’25	(73)	(55)	(62)	(45)	(235)
’24	(50)	(66)	(75)	(58)	(249)
’23	(67)	(69)	(75)	(89)	(300)
’22	(49)	(57)	(66)	(57)	(229)
’21	47	(28)	(53)	(40)	(74)
’20	(22)	(21)	(24)	(35)	(102)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(51)	(54)	—	—	—
’25	(74)	(55)	(62)	(45)	(236)
’24	(52)	(66)	(75)	(58)	(251)
’23	(69)	(70)	(76)	(89)	(304)
’22	(52)	(59)	(68)	(59)	(239)
’21	46	(29)	(55)	(41)	(78)
’20	(23)	(21)	(24)	(35)	(104)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	83	3	1	26	10	15	11		(28.6%)	11	18	35	+32.2%
	Gross margin, %	—	—	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		+100.0 pt	Powerpack Relay Therapeutics, Inc.’s next three years, line by line Analysts expect revenue to grow 32.2% a year to 2028 — faster than the −28.6% of the last 5 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	(49)	(75)	(52)	(364)	(291)	(342)	(338)	(276)	(286)		+28.1%
	EBT margin, %	—	—	0.00	0.00	(63.41)	(12,012.94)	(21,036.13)	(1,338.66)	(3,374.72)	(1,800.58)	(2,594.20)		(1,800.6) pt
	Net income	—	0	(49)	(75)	(52)	(364)	(291)	(342)	(338)	(276)	(286)		n/m
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	1.94	0.03	0.01	0.21	0.07	0.09	0.05		n/m
	Earnings	—	—	(0.54)	(21.82)	(5.40)	(3.82)	(2.59)	(2.79)	(2.36)	(1.61)	(1.57)		+16.9%
	Cash flow	—	—	(0.49)	(19.16)	(2.40)	(0.78)	(2.04)	(2.45)	(1.74)	(1.37)	(1.05)		+15.8%
	Capex	—	—	0.00	(2.31)	(0.05)	(0.04)	(0.08)	(0.03)	(0.01)	0.00	0.00		n/m
	Free cash flow	—	—	(0.49)	(21.48)	(2.45)	(0.82)	(2.13)	(2.48)	(1.76)	(1.37)	(1.05)		+15.8%
	Book value	—	—	4.68	(52.29)	17.91	9.44	8.47	6.13	5.44	3.30	4.39		(4.9%)
	Shares, m	—	—	90	3	43	95	112	123	143	172	182		+9.7%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	—	0.00	964.56	1,222.30	56.91	16.66	57.24	313.49		386.3
	P/B	—	—	—	—	2.32	3.25	1.78	1.93	0.76	2.56	3.88		2.1
	EV/Sales	—	—	—	—	0.00	648.26	498.97	27.55	(5.45)	35.37	230.87		200.8
	EV/FCF	—	—	—	—	(10.47)	(25.21)	(2.89)	(2.31)	0.77	(3.80)	(11.97)		(7.3)
Cash, $m
Cash, $m	Operating cash flow	—	—	(44)	(66)	(102)	(74)	(229)	(300)	(249)	(235)	(212)		+27.0%
	Capex	—	—	(2)	(8)	(2)	(3)	(9)	(4)	(2)	0	0		(18.3%)
	Free cash flow	—	—	(44)	(74)	(104)	(78)	(239)	(304)	(251)	(236)	(212)		+27.1%
Balance, $m
Balance, $m	Working capital	—	—	417	349	756	952	956	740	758	553	877		+4.1%
	Net debt	—	—	(422)	(356)	(678)	(958)	(999)	(750)	(781)	(555)	(911)		+4.0%
	Shareholders’ equity	—	—	421	(180)	763	898	950	752	778	567	890		+4.3%
Returns, %
Returns, %	ROA	—	—	(22.74)	(18.32)	(38.60)	(40.25)	(27.56)	(35.19)	(39.38)	(37.05)	(33.72)		(14.3) pt
	ROIC	—	—	0.00	0.00	(40.91)	0.00	0.00	(12,160.29)	0.00	(1,508.62)	0.00		(1,508.6) pt
	ROE	—	—	33.53	51.68	(78.99)	(43.81)	(31.44)	(40.18)	(44.15)	(41.12)	(36.77)		(74.6) pt
People
People	Employees	—	—	—	122	159	245	327	323	261	192	—		+7.9%
	Revenue/emp, $m	—	—	—	0.00	0.52	0.01	0.00	0.08	0.04	0.08	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
EWTX Edgewise Therapeutics, Inc.	$4.2B	— (loss-making)	—	—	n/m	−30.24% (below 0%: shrinking)	0.00%	0.00%	Compare
RLAY Relay Therapeutics, Inc.	$3.7B	— (loss-making)	— (loss-making)	−95.44% (below 0%: shrinking)	n/m	+2.13% (above 0%: growing)	100.00%	(25,949.71%)
ACAD ACADIA Pharmaceuticals Inc.	$3.7B	10.0×	33.4×	+22.85% (above 0%: growing)	−27.91% (below 0%: shrinking)	+141.15% (above 0%: growing)	89.75%	20.95%	Compare
XENE Xenon Pharmaceuticals Inc.	$3.7B	— (loss-making)	— (loss-making)	+100.70% (above 0%: growing)	n/m	−48.57% (below 0%: shrinking)	100.00%	0.00%	Compare
ABCL AbCellera Biologics Inc.	$3.6B	— (loss-making)	— (loss-making)	−76.29% (below 0%: shrinking)	n/m	+151.98% (above 0%: growing)	100.00%	(1,550.05%)	Compare
TNGX Tango Therapeutics, Inc.	$3.5B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−4.58% (below 0%: shrinking)	0.00%	0.00%	Compare
IOVA Iovance Biotherapeutics, Inc.	$3.5B	— (loss-making)	— (loss-making)	+80.07% (above 0%: growing)	n/m	+89.72% (above 0%: growing)	0.00%	(19.73%)	Compare
IRON Disc Medicine, Inc.	$3.5B	— (loss-making)	—	—	n/m	+7.83% (above 0%: growing)	0.00%	0.00%	Compare
PBLS Parabilis Medicines, Inc.	$3.4B	— (loss-making)	—	—	n/m	—	100.00%	(34,382.43%)	Compare
Median of peers	$3.6B	—	—	+22.85%	—	+7.83%	44.88%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 April 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	4.65m	9.12m	20.36
2024	13.08m	(1.28m)	9.91
2023	19.77m	5.29m	26.49
2022	8.12m	(5.23m)	35.95
2021	8.53m	(3.35m)	73.89

Ownership

Directors and executive officers, together 5.04%

SVF Pauling (Cayman) Limited 14.75%

Commodore Capital LP 8.98%

Point72 Asset Management, L.P. 7.11%

Casdin Capital 6.87%

BlackRock, Inc. 5.45%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Relay Therapeutics, Inc. (RLAY) Latest News

4 Nov

Impact 3 · 4:05 PM · GlobeNewswire

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

28 Oct

Impact 3 · 4:12 PM · GlobeNewswire

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

8 Oct

Impact 3 · 2:12 AM · Simply Wall St.

Relay Therapeutics (RLAY) Stock Looks Fully Priced On Book Value

7 Oct

Impact 3 · 10:10 PM · Simply Wall St.

Is Relay Therapeutics (RLAY) Cheap After Its Pullback Or Is The Upside Priced In?

24 Sep

Impact 3 · 11:08 AM · Zacks

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

22 Sep

Impact 4 · 9:30 AM · GlobeNewswire

X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics

3 Sep

Impact 4 · 10:32 AM

Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?

20 Aug

Impact 4 · 8:01 AM

This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion

19 Aug

Impact 3 · 8:16 PM

Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified?

13 Aug

Impact 3 · 11:00 AM · Barchart

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year

6 Aug

Impact 3 · 4:05 PM

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

11 Jun

Impact 3 · 6:20 AM · Insider Monkey

Relay Therapeutics (RLAY) is One of the Best AI Driven Biotech Stocks, Here is Why

22 May

Impact 4 · 5:50 PM · The Motley Fool

Is Relay Therapeutics a Buy After Promising Trial Results?

21 May

Impact 3 · 10:16 PM · Simply Wall St.

Relay Therapeutics (RLAY) Is Up 6.9% After Follow-On Offering And Early Zovegalisib Data Release

20 May

Impact 3 · 8:21 PM · GlobeNewswire

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

Impact 3 · 7:21 PM · The Motley Fool

Why Relay Therapeutics Stock Popped on Wednesday

19 May

Impact 4 · 9:31 AM · InvestorsHub

Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY)

Impact 4 · 6:00 AM · Investor's Business Daily

This Biotech's Drug Just Wiped The Floor With Forecasts

Impact 4 · 6:00 AM · GlobeNewswire

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

Impact 4 · 4:05 AM · biopharmadive.com

Relay drug shows early promise against rare blood vessel diseases

Impact 3 · 4:03 PM · GlobeNewswire

Relay Therapeutics Announces Proposed Public Offering of Common Stock

8 May

Impact 3 · 10:11 AM · Simply Wall St.

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know

5 May

Impact 4 · 4:05 PM · GlobeNewswire

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

2 May

Impact 4 · 12:28 AM · Simply Wall St.

Relay Therapeutics Advances Zovegalisib To Phase 3 As Valuation Gap Persists

28 Apr

Impact 4 · 1:04 AM · MarketBeat

Relay Therapeutics Unveils Zovegalisib Triplet Data, Signs Pfizer Supply Deal for Phase III Plan

27 Apr

Impact 4 · 6:00 AM · GlobeNewswire

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

4 Apr

Impact 4 · 12:13 PM · Simply Wall St.

Relay Therapeutics (RLAY) Is Up 30.6% After Expanding Zovegalisib Into Vascular Anomalies Data Reveal

3 Apr

Impact 4 · 2:41 AM · Insider Monkey

Relay Therapeutics (RLAY) Climbs 16% Ahead of Cancer Treatment Update

2 Apr

Impact 3 · 4:05 PM · GlobeNewswire

Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

16 Mar

Impact 4 · 7:00 AM · GlobeNewswire

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Relay Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 28 April 2026

Chief executive’s pay

Ownership

Relay Therapeutics, Inc. (RLAY) Latest News

4 Nov

28 Oct

8 Oct

7 Oct

24 Sep

22 Sep

3 Sep

20 Aug

19 Aug

13 Aug

6 Aug

11 Jun

22 May

21 May

20 May

19 May

8 May

5 May

2 May

28 Apr

27 Apr

4 Apr

3 Apr

2 Apr

16 Mar

RLAY metrics, ten years each

Stockrow Weekly